Drug development concerning metallo-β-lactamases in gram-negative bacteria
β-Lactams have been a clinical focus since their emergence and indeed act as a powerful tool to combat severe bacterial infections, but their effectiveness is threatened by drug resistance in bacteria, primarily by the production of serine- and metallo-β-lactamases. Although once of less clinical re...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2022.959107/full |
| _version_ | 1811261781964750848 |
|---|---|
| author | Xiuyun Li Jing Zhao Bin Zhang Xuexia Duan Jin Jiao Weiwei Wu Yuxia Zhou Hefeng Wang |
| author_facet | Xiuyun Li Jing Zhao Bin Zhang Xuexia Duan Jin Jiao Weiwei Wu Yuxia Zhou Hefeng Wang |
| author_sort | Xiuyun Li |
| collection | DOAJ |
| description | β-Lactams have been a clinical focus since their emergence and indeed act as a powerful tool to combat severe bacterial infections, but their effectiveness is threatened by drug resistance in bacteria, primarily by the production of serine- and metallo-β-lactamases. Although once of less clinical relevance, metallo-β-lactamases are now increasingly threatening. The rapid dissemination of resistance mediated by metallo-β-lactamases poses an increasing challenge to public health worldwide and comprises most existing antibacterial chemotherapies. Regrettably, there have been no clinically available inhibitors of metallo-β-lactamases until now. To cope with this unique challenge, researchers are exploring multidimensional strategies to combat metallo-β-lactamases. Several studies have been conducted to develop new drug candidates or calibrate already available drugs against metallo-β-lactamases. To provide an overview of this field and inspire more researchers to explore it further, we outline some promising candidates targeting metallo-β-lactamase producers, with a focus on Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Promising candidates in this review are composed of new antibacterial drugs, non-antibacterial drugs, antimicrobial peptides, natural products, and zinc chelators, as well as their combinations with existing antibiotics. This review may provide ideas and insight for others to explore candidate metallo-β-lactamases as well as promote the improvement of existing data to obtain further convincing evidence. |
| first_indexed | 2024-04-12T19:12:01Z |
| format | Article |
| id | doaj.art-09c73fcb791d46c5bbfb65e879d450c1 |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-04-12T19:12:01Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-09c73fcb791d46c5bbfb65e879d450c12022-12-22T03:19:50ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2022-09-011310.3389/fmicb.2022.959107959107Drug development concerning metallo-β-lactamases in gram-negative bacteriaXiuyun Li0Jing Zhao1Bin Zhang2Xuexia Duan3Jin Jiao4Weiwei Wu5Yuxia Zhou6Hefeng Wang7Maternal and Child Health Development Research Center, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, ChinaPharmaceutical Department, Shandong Provincial Taishan Hospital, Taian, ChinaDepartment of Ophthalmology, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, ChinaPhysical Examination Center, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, ChinaDepartment of Clinical Laboratory, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, ChinaDepartment of Clinical Laboratory, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, ChinaDepartment of Clinical Laboratory, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, ChinaDepartment of Pediatric Surgery, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, Chinaβ-Lactams have been a clinical focus since their emergence and indeed act as a powerful tool to combat severe bacterial infections, but their effectiveness is threatened by drug resistance in bacteria, primarily by the production of serine- and metallo-β-lactamases. Although once of less clinical relevance, metallo-β-lactamases are now increasingly threatening. The rapid dissemination of resistance mediated by metallo-β-lactamases poses an increasing challenge to public health worldwide and comprises most existing antibacterial chemotherapies. Regrettably, there have been no clinically available inhibitors of metallo-β-lactamases until now. To cope with this unique challenge, researchers are exploring multidimensional strategies to combat metallo-β-lactamases. Several studies have been conducted to develop new drug candidates or calibrate already available drugs against metallo-β-lactamases. To provide an overview of this field and inspire more researchers to explore it further, we outline some promising candidates targeting metallo-β-lactamase producers, with a focus on Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Promising candidates in this review are composed of new antibacterial drugs, non-antibacterial drugs, antimicrobial peptides, natural products, and zinc chelators, as well as their combinations with existing antibiotics. This review may provide ideas and insight for others to explore candidate metallo-β-lactamases as well as promote the improvement of existing data to obtain further convincing evidence.https://www.frontiersin.org/articles/10.3389/fmicb.2022.959107/fullantibiotic resistancemetallo-β-lactamasesnovel drug strategiesEscherichia coliKlebsiella pneumoniaePseudomonas aeruginosa |
| spellingShingle | Xiuyun Li Jing Zhao Bin Zhang Xuexia Duan Jin Jiao Weiwei Wu Yuxia Zhou Hefeng Wang Drug development concerning metallo-β-lactamases in gram-negative bacteria Frontiers in Microbiology antibiotic resistance metallo-β-lactamases novel drug strategies Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa |
| title | Drug development concerning metallo-β-lactamases in gram-negative bacteria |
| title_full | Drug development concerning metallo-β-lactamases in gram-negative bacteria |
| title_fullStr | Drug development concerning metallo-β-lactamases in gram-negative bacteria |
| title_full_unstemmed | Drug development concerning metallo-β-lactamases in gram-negative bacteria |
| title_short | Drug development concerning metallo-β-lactamases in gram-negative bacteria |
| title_sort | drug development concerning metallo β lactamases in gram negative bacteria |
| topic | antibiotic resistance metallo-β-lactamases novel drug strategies Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2022.959107/full |
| work_keys_str_mv | AT xiuyunli drugdevelopmentconcerningmetalloblactamasesingramnegativebacteria AT jingzhao drugdevelopmentconcerningmetalloblactamasesingramnegativebacteria AT binzhang drugdevelopmentconcerningmetalloblactamasesingramnegativebacteria AT xuexiaduan drugdevelopmentconcerningmetalloblactamasesingramnegativebacteria AT jinjiao drugdevelopmentconcerningmetalloblactamasesingramnegativebacteria AT weiweiwu drugdevelopmentconcerningmetalloblactamasesingramnegativebacteria AT yuxiazhou drugdevelopmentconcerningmetalloblactamasesingramnegativebacteria AT hefengwang drugdevelopmentconcerningmetalloblactamasesingramnegativebacteria |